William P Farrar

US Patent:

58344292, Nov 10, 1998

Filed:

Aug 13, 1993

Appl. No.:

8/105926

Inventors:

Candance B. Pert - Bethesda MD
Michael R. Ruff - Bethesda MD
William L. Farrar - Gaithersburg MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3804
A61K 3808

US Classification:

514 16

Abstract:

Short peptide of the formula: R. sup. a -Ser-Thr-Thr-Thr-Asn-Tyr-R. sup. b (I) where R. sup. a represents an amino terminal residue Ala- or D-Ala and R. sup. b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II): R. sup. 1 -R. sup. 2 -R. sup. 3 -R. sup. 4 -R. sup. 5 (II) where R. sup. 1 is an amino terminal residue Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu- R. sup. 2 is Thr, Ser or Asp R. sup. 3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp R. sup. 4 is Tyr and R. sup. 5 is a carboxy terminal amnio group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, or a physiologically acceptable salt thereof. Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors.

US Patent:

52760162, Jan 4, 1994

Filed:

Aug 16, 1990

Appl. No.:

7/568616

Inventors:

Candace B. Pert - Bethesda MD
Michael R. Ruff - Bethesda MD
William L. Farrar - Gaithersburg MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3702
C07K 706

US Classification:

514 15

Abstract:

Short peptide of the formula: R. sup. a -Ser-Thr-Thr-Thr-Asn-Tyr-R. sup. b (I) where R. sup. a represents an amino terminal residue Ala- or D-Ala and R. sup. b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II): R. sup. 1 -R. sup. 2 -R. sup. 3 -R. sup. 4 -R. sup. 5 (II) where R. sup. 1 is an amino terminal residue Thr-, Ser-, Asn-,Leu-,Ile-,Arg- or Glu- R. sup. 2 is Thr, Ser or Asp R. sup. 3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp R. sup. 4 is Tyr and R. sup. 5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, or a physiologically acceptable salt thereof. Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors.

US Patent:

58637184, Jan 26, 1999

Filed:

Jun 7, 1995

Appl. No.:

8/486678

Inventors:

Candance B. Pert - Bethesda MD
Michael R. Ruff - Bethesda MD
William L. Farrar - Gaithersburg MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C12Q 170
G01N 3353
A61K 3804
C07K 500

US Classification:

435 5

Abstract:

Short peptide of the formula: R. sup. a -Ser-Thr-Thr-Thr-Asn-Tyr-R. sup. b (I) where R. sup. a represents an amino terminal residue Ala- or D-Ala and R. sup. b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II): R. sup. 1 -R. sup. 2 -R. sup. 3 -R. sup. 4 -R. sup. 5 (II) where R. sup. l is an amino terminal residue Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu- R. sup. 2 is Thr, Ser or Asp R. sup. 3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp R. sup. 4 is Tyr and R. sup. 5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, or a physiologically acceptable salt thereof. Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors.